4D Molecular Therapeutics, Inc.
NASDAQ4D Molecular Therapeutics reports Q1 results today with short sellers holding one of the heaviest positions in the biotech space. Short interest has climbed sharply into the print. At 20.7% of the free float — up 18% over the past month and 4.6% over the past week — the short position ranks in just the 11th percentile of the broader universe on the short score ranking, meaning…
Snapshot as of 23 Jun 2026
4D Molecular Therapeutics reports Q1 results today with short sellers holding one of the heaviest positions in the biotech space. Short interest has climbed sharply into the print. At 20.7% of the free float — up 18%…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for FDMT — free to start on ORTEX.
Sign up for free →Open FDMT on ORTEX